食品和药物管理局批准TRYNGOLZA对患有罕见基因障碍导致高三环酸浓度的成年人适用。 The FDA approves TRYNGOLZA for adults with a rare genetic disorder causing high triglyceride levels.

美国食品和药物管理局批准TRYNGOLZA (olezarsen) 作为治疗家族性胆小血症综合征 (FCS) 的成年人的首例治疗,这是一种罕见的遗传疾病,导致三糖水平极高. The FDA has approved TRYNGOLZA (olezarsen) as the first treatment for adults with familial chylomicronemia syndrome (FCS), a rare genetic disorder causing extremely high triglyceride levels. 在临床试验中，该药物每月通过自动注射器给药，可显著降低甘油三酯水平和急性胰腺炎事件。 The drug, administered monthly via an auto-injector, significantly reduced triglyceride levels and acute pancreatitis events in clinical trials. 它与对患有FCS的病人的饮食管理同时使用,这影响到美国多达3,000人,其中许多人仍未诊断。 It is used alongside dietary management for patients with FCS, which affects up to 3,000 people in the USA, many of whom remain undiagnosed.